EA201100763A1 - Методы получения хинолиновых производных - Google Patents

Методы получения хинолиновых производных

Info

Publication number
EA201100763A1
EA201100763A1 EA201100763A EA201100763A EA201100763A1 EA 201100763 A1 EA201100763 A1 EA 201100763A1 EA 201100763 A EA201100763 A EA 201100763A EA 201100763 A EA201100763 A EA 201100763A EA 201100763 A1 EA201100763 A1 EA 201100763A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
quinoline derivatives
producing quinoline
producing
compound
Prior art date
Application number
EA201100763A
Other languages
English (en)
Other versions
EA019247B1 (ru
Inventor
Джо Энн Уилсон
Шарик Зубери
Срирам Наганатхан
Эрик Голдман
Джеймс Кантер
Original Assignee
Экселиксис, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Экселиксис, Инк. filed Critical Экселиксис, Инк.
Publication of EA201100763A1 publication Critical patent/EA201100763A1/ru
Publication of EA019247B1 publication Critical patent/EA019247B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4

Abstract

Методы получения соединения с формулой i(l)или фармацевтически приемлемой соли этого соединения, где Rи Rвместе с атомом азота, к которому они присоединены, образуют 6-членную гетероциклоалкильную группу; X- H, Br, Cl или F; X- H, Br, Cl или F; s равно 2-6; n1 равно 1-2; n2 равно 1-2.
EA201100763A 2008-11-13 2009-11-13 Способы получения хинолиновых производных EA019247B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19908808P 2008-11-13 2008-11-13
PCT/US2009/064341 WO2010056960A1 (en) 2008-11-13 2009-11-13 Methods of preparing quinoline derivatives

Publications (2)

Publication Number Publication Date
EA201100763A1 true EA201100763A1 (ru) 2011-10-31
EA019247B1 EA019247B1 (ru) 2014-02-28

Family

ID=41665615

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201100763A EA019247B1 (ru) 2008-11-13 2009-11-13 Способы получения хинолиновых производных

Country Status (14)

Country Link
US (1) US20130197230A1 (ru)
EP (1) EP2350011A1 (ru)
JP (1) JP5486606B2 (ru)
KR (1) KR20110084455A (ru)
CN (1) CN102282134B (ru)
AU (1) AU2009313970A1 (ru)
CA (1) CA2743416A1 (ru)
EA (1) EA019247B1 (ru)
IL (1) IL212810A (ru)
MX (1) MX2011005038A (ru)
NZ (1) NZ592827A (ru)
TW (1) TW201022258A (ru)
WO (1) WO2010056960A1 (ru)
ZA (1) ZA201103480B (ru)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5734193B2 (ja) 2008-10-14 2015-06-17 クイ ニング 化合物及び使用方法
TWI577664B (zh) 2009-01-16 2017-04-11 艾克塞里克斯公司 Ｎ-（４-｛〔６，７-雙（甲氧基）喹啉-４-基〕氧基｝苯基）-ｎ’-（４-氟苯基）環丙烷-１，１-二甲醯胺蘋果酸鹽、包含其之醫藥組合物及其用途
RU2011142597A (ru) 2009-03-21 2013-04-27 Саншайн Лейк Фарма Ко., Лтд. Производные сложных эфиров аминокислот, их соли и способы применения
EP2454238A1 (en) 2009-07-17 2012-05-23 Exelixis, Inc. Crystalline forms of n-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]-quinolin-4-yl}oxy)phenyl]-n'-(4-fluorophenyl)cyclopropane-1, 1-dicarboxamide
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
US9724342B2 (en) 2010-07-16 2017-08-08 Exelixis, Inc. C-met modulator pharmaceutical compositions
AU2011307304C1 (en) 2010-09-27 2016-10-20 Exelixis, Inc. Dual inhibitors of MET and VEGF for the treatment of castration- resistant prostate cancer and osteoblastic bone metastases
CA2826751C (en) 2011-02-10 2021-05-18 Exelixis, Inc. Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds
US20120252840A1 (en) 2011-04-04 2012-10-04 Exelixis, Inc. Method of Treating Cancer
WO2012151326A1 (en) 2011-05-02 2012-11-08 Exelixis, Inc. Method of treating cancer and bone cancer pain
EA201490676A1 (ru) 2011-09-22 2015-02-27 Экселиксис, Инк. Способ лечения остеопороза
JP6208140B2 (ja) * 2011-10-20 2017-10-04 エクセリクシス， インク． キノリン誘導体の調製プロセス
EP2844254A1 (en) 2012-05-02 2015-03-11 Exelixis, Inc. A dual met - vegf modulator for treating osteolytic bone metastases
CN103664776B (zh) * 2012-09-26 2016-05-04 正大天晴药业集团股份有限公司 一种酪氨酸激酶抑制剂及其中间体的制备方法
CN103965104B (zh) * 2013-01-29 2017-09-29 正大天晴药业集团股份有限公司 一种酪氨酸激酶抑制剂及其中间体的制备方法
CA2907334C (en) 2013-03-15 2021-12-07 Exelixis, Inc. Metabolites of n-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
WO2014165786A1 (en) 2013-04-04 2014-10-09 Exelixis, Inc. Cabozantinib dosage form and use in the treatment of cancer
MX2016010266A (es) 2014-02-14 2017-02-08 Exelixis Inc Formas solidas cristalinas de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi ]fenil}-n'-(4-fluorofenil)ciclopropan-1,1-dicarboxamida, procesos para elaboracion y metodos de uso.
US10159666B2 (en) 2014-03-17 2018-12-25 Exelixis, Inc. Dosing of cabozantinib formulations
ES2929888T3 (es) 2014-07-31 2022-12-02 Exelixis Inc Procedimiento para preparar cabozantinib marcado con flúor 18 y sus análogos
UA121482C2 (uk) 2014-08-05 2020-06-10 Екселіксіс, Інк. Комбінація інгібітору протеасом, яким є бортезоміб, та інгібітору c-met для лікування множинної мієломи
CN105218445B (zh) * 2015-08-25 2018-05-22 江苏中邦制药有限公司 一种酪氨酸激酶抑制剂Foretinib的制备方法
CN109069499A (zh) 2016-04-15 2018-12-21 埃克塞里艾克西斯公司 使用 n-(4-(6,7-二甲氧基喹啉-4-基氧基)苯基)-n’-(4-氟苯基)环丙烷-1,1-二甲酰胺,(2s)-羟基丁二酸盐治疗肾细胞癌的方法
CN109824587A (zh) * 2017-11-23 2019-05-31 上海翔锦生物科技有限公司 酪氨酸激酶抑制剂xjf007及其中间体的制备方法
CN113710322A (zh) 2019-01-25 2021-11-26 埃克塞里艾克西斯公司 用于治疗激酶依赖性病症的化合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU733551B2 (en) * 1996-09-25 2001-05-17 Astrazeneca Ab Qinoline derivatives inhibiting the effect of growth factors such as VEGF
CN100415720C (zh) * 2001-06-22 2008-09-03 麒麟医药株式会社 喹啉衍生物和喹唑啉衍生物以及含有这些化合物的药物组合物
EP2609919A3 (en) * 2003-09-26 2014-02-26 Exelixis, Inc. c-Met modulators and methods of use
WO2006108059A1 (en) * 2005-04-06 2006-10-12 Exelixis, Inc. C-met modulators and methods of use
MX2008011220A (es) * 2006-03-07 2008-09-11 Array Biopharma Inc Compuestos de pirazol heterobiciclicos y metodos de uso.
US20080004273A1 (en) * 2006-05-30 2008-01-03 Stephane Raeppel Inhibitors of protein tyrosine kinase activity

Also Published As

Publication number Publication date
IL212810A0 (en) 2011-07-31
NZ592827A (en) 2013-06-28
EP2350011A1 (en) 2011-08-03
KR20110084455A (ko) 2011-07-22
AU2009313970A1 (en) 2010-05-20
CN102282134B (zh) 2015-04-01
JP5486606B2 (ja) 2014-05-07
TW201022258A (en) 2010-06-16
CN102282134A (zh) 2011-12-14
WO2010056960A1 (en) 2010-05-20
JP2012508763A (ja) 2012-04-12
US20130197230A1 (en) 2013-08-01
MX2011005038A (es) 2011-06-16
IL212810A (en) 2013-07-31
ZA201103480B (en) 2012-01-25
CA2743416A1 (en) 2010-05-20
EA019247B1 (ru) 2014-02-28

Similar Documents

Publication Publication Date Title
EA201100763A1 (ru) Методы получения хинолиновых производных
CY1124582T1 (el) Μεθοδος παραγωγης ενωσεων που εχουν δρασης αναστολης ιντεγκρασης hiv
CY1119049T1 (el) Υποκατεστημενα πυρρολιδινο-2-καρβοξαμιδια
EA201291409A1 (ru) Производные индолизина, способ их получения и их терапевтическое применение
PH12014501719A1 (en) Pyridone derivatives
EA201391180A1 (ru) Способ получения оптически активных производных дигидробензофурана
EA201291414A1 (ru) Имидазопиридиновые производные, способ их получения и терапевтическое использование
MA35452B1 (fr) 3-pyrimidin-4-yl-oxazolidin-2-ones comme inhibiteurs d'idh mutante
CR11021A (es) Derivados de quinolina como fungicidas
EA201700230A1 (ru) Определенные аминопиридины, композиции на их основе и способы их применения
AR082799A1 (es) Derivados de quinolina y quinoxalina como inhibidores de quinasa
MD20180040A2 (ru) Ингибиторы вируса гепатита С
ATE459622T1 (de) Tropanverbindungen
MX2009004920A (es) Nuevos derivados de aminopirimidina como inhibidores de plk1.
EA201000883A1 (ru) Производные индолинона и способ их получения
MX2014000452A (es) Derivados de azabencimiazol que tiene actividad activadora de la proteina cinasa activada monofosfato de denosina (ampk).
WO2012042534A3 (en) Preparation of r-sitagliptin and intermediates thereof
UA109525C2 (xx) Алкіламідна сполука і її застосування
EP2566477A4 (en) AMINO-QUINOLINES AS KINASE INHIBITORS
RS54183B1 (en) PIRAZOLE DERIVATIVES
CY1112079T1 (el) Νεες ενωσεις ως ανταγωνιστες των α1 υποδοχεων αδενοσινης
JO3318B1 (ar) مثبطات bace
EA201492255A1 (ru) Феноксиэтилпиперидиновые соединения
EP2581372A4 (en) CYANOCHINOLINDERIVATE
EA201991921A1 (ru) Способы получения ag-10, его промежуточных соединений и их солей

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU